The Costs of Industry-Sponsored Drug Trials in Canada
This study, published in PharmacoEconomics – Open, reports exploratory analysis of the provincial and nationwide costs of industry-sponsored drug clinical trials (CTs) in Canada. The costs of industry-sponsored drug CTs completed in 2016 when measured in terms of market prices in Canada were valued at $Can2.1 billion. In addition to the creation of knowledge, these trials play an important role in alleviating the healthcare cost burden in Canada. Appropriate policy should be in place to foster industry investments in clinical research to advance both scientific and economic merits. This research was funded with an unrestricted grant from Innovative Medicines Canada.
Year of Publication: 2019
Authors: Dat Tran, Ilke Akpinar, Philip Jacobs
Journal Title: PharmacoEconomics - Open